
Niek N Sanders

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9376467/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through TAcell-mediated immunity. Molecular Therapy, 2022, 30, 2968-2983.	8.2	20
2	InÂVivo Validation of a Reversible Small Molecule-Based Switch for Synthetic Self-Amplifying mRNA Regulation. Molecular Therapy, 2021, 29, 1164-1173.	8.2	13
3	Lipid-Polyglutamate Nanoparticle Vaccine Platform. ACS Applied Materials & Interfaces, 2021, 13, 6011-6022.	8.0	20
4	Corticosteroids and mRNA Vaccines: A Word of Caution. Molecular Therapy, 2021, 29, 893-894.	8.2	1
5	Sterilizing Immunity against SARSâ€CoVâ€2 Infection in Mice by a Singleâ€Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonistâ€Adjuvanted Recombinant Spike Protein Vaccine**. Angewandte Chemie - International Edition, 2021, 60, 9467-9473.	13.8	45
6	Sterilizing Immunity against SARSâ€CoVâ€2 Infection in Mice by a Singleâ€Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonistâ€Adjuvanted Recombinant Spike Protein Vaccine**. Angewandte Chemie, 2021, 133, 9553-9559.	2.0	4
7	Corticosteroids and cellulose purification improve, respectively, the inÂvivo translation and vaccination efficacy of sa-mRNAs. Molecular Therapy, 2021, 29, 1370-1381.	8.2	15
8	Low-dose single-shot COVID-19 mRNA vaccines lie ahead. Molecular Therapy, 2021, 29, 1944-1945.	8.2	5
9	Squaric Ester-Based, pH-Degradable Nanogels: Modular Nanocarriers for Safe, Systemic Administration of Toll-like Receptor 7/8 Agonistic Immune Modulators. Journal of the American Chemical Society, 2021, 143, 9872-9883.	13.7	36
10	Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across. Advanced Drug Delivery Reviews, 2021, 176, 113900.	13.7	59
11	Antibody-Mediated Targeting of Antigens to Intestinal Aminopeptidase N Elicits Gut IgA Responses in Pigs. Frontiers in Immunology, 2021, 12, 753371.	4.8	2
12	Mucosal Vaccination Against Periodontal Disease: Current Status and Opportunities. Frontiers in Immunology, 2021, 12, 768397.	4.8	14
13	Immune cells as tumor drug delivery vehicles. Journal of Controlled Release, 2020, 327, 70-87.	9.9	53
14	Imidazoquinoline-Conjugated Degradable Coacervate Conjugate for Local Cancer Immunotherapy. ACS Biomaterials Science and Engineering, 2020, 6, 4993-5000.	5.2	13
15	The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration. Molecular Therapy - Nucleic Acids, 2020, 22, 373-381.	5.1	33
16	Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles. Journal of the American Chemical Society, 2020, 142, 12133-12139.	13.7	52
17	Chlamydia: what is on the outside does matter. Critical Reviews in Microbiology, 2020, 46, 100-119.	6.1	12
18	Potent Lymphatic Translocation and Spatial Control Over Innate Immune Activation by Polymer–Lipid Amphiphile Conjugates of Smallâ€Molecule TLR7/8 Agonists. Angewandte Chemie - International Edition, 2019, 58, 15390-15395.	13.8	43

#	Article	IF	CITATIONS
19	Amphiphile Polymerâ€Lipidkonjugate zur potenten lymphatischen Anreicherung von TLR7/8â€Agonisten ermöglichen eine örtlich begrenzte Aktivierung des angeborenen Immunsystems. Angewandte Chemie, 2019, 131, 15535-15541.	2.0	5
20	Improving the Repeatability and Efficacy of Intradermal Electroporated Self-Replicating mRNA. Molecular Therapy - Nucleic Acids, 2019, 17, 388-395.	5.1	11
21	Chlamydial Infection From Outside to Inside. Frontiers in Microbiology, 2019, 10, 2329.	3.5	53
22	Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine. Vaccines, 2019, 7, 96.	4.4	40
23	Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin. Molecular Therapy - Nucleic Acids, 2019, 17, 867-878.	5.1	44
24	Mononuclear but Not Polymorphonuclear Phagocyte Depletion Increases Circulation Times and Improves Mammary Tumor-Homing Efficiency of Donor Bone Marrow-Derived Monocytes. Cancers, 2019, 11, 1752.	3.7	5
25	Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer. Frontiers in Immunology, 2019, 10, 2928.	4.8	25
26	Comparison of the Expression Kinetics and Immunostimulatory Activity of Replicating mRNA, Nonreplicating mRNA, and pDNA after Intradermal Electroporation in Pigs. Molecular Pharmaceutics, 2018, 15, 377-384.	4.6	22
27	mRNA therapeutics deliver a hopeful message. Nano Today, 2018, 23, 16-39.	11.9	90
28	Nanoparticle onjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses. Advanced Materials, 2018, 30, e1803397.	21.0	120
29	Lymph-Node-Targeted Immune Activation by Engineered Block Copolymer Amphiphiles–TLR7/8 Agonist Conjugates. Journal of the American Chemical Society, 2018, 140, 14300-14307.	13.7	50
30	Small-molecule-based regulation of RNA-delivered circuits in mammalian cells. Nature Chemical Biology, 2018, 14, 1043-1050.	8.0	52
31	Off-Target and Tumor-Specific Accumulation of Monocytes, Macrophages and Myeloid-Derived Suppressor Cells after Systemic Injection. Neoplasia, 2018, 20, 848-856.	5.3	14
32	Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2018, 37, 191.	8.6	50
33	Oral delivery of Escherichia coli persistently infected with M2e-displaying bacteriophages partially protects against influenza A virus. Journal of Controlled Release, 2017, 264, 55-65.	9.9	16
34	Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice. Cancer Immunology, Immunotherapy, 2017, 66, 1545-1555.	4.2	3
35	Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study. Cancer Letters, 2017, 400, 205-218.	7.2	18
36	Comparison of the Adipose and Luminal Mammary Gland Compartment as Orthotopic Inoculation Sites in a 471-Based Immunocompetent Preclinical Model for Triple-Negative Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2016, 21, 113-122.	2.7	10

#	Article	IF	CITATIONS
37	Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. Molecular Therapy, 2016, 24, 2012-2020.	8.2	88
38	Coadministration of a Plasmid Encoding HIV-1 Gag Enhances the Efficacy of Cancer DNA Vaccines. Molecular Therapy, 2016, 24, 1686-1696.	8.2	18
39	Topical imiquimod yields systemic effects due to unintended oral uptake. Scientific Reports, 2016, 6, 20134.	3.3	29
40	Aerosolized Non-viral Nucleic Acid Delivery in the Vaginal Tract of Pigs. Pharmaceutical Research, 2016, 33, 384-394.	3.5	20
41	Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs. Oncotarget, 2016, 7, 10905-10916.	1.8	18
42	N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. Journal of Controlled Release, 2015, 217, 337-344.	9.9	365
43	Synthetic biology devices and circuits for RNA-based â€~smart vaccines': a propositional review. Expert Review of Vaccines, 2015, 14, 313-331.	4.4	33
44	Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?. OncoImmunology, 2015, 4, e1048413.	4.6	6
45	Vaccination of Mice Using the West Nile Virus E-Protein in a DNA Prime-Protein Boost Strategy Stimulates Cell-Mediated Immunity and Protects Mice against a Lethal Challenge. PLoS ONE, 2014, 9, e87837.	2.5	32
46	Non-Classical ProIL-1beta Activation during Mammary Gland Infection Is Pathogen-Dependent but Caspase-1 Independent. PLoS ONE, 2014, 9, e105680.	2.5	33
47	Various ways to improve whole cancer cell vaccines. Expert Review of Vaccines, 2014, 13, 721-735.	4.4	39
48	Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. Journal of Controlled Release, 2014, 187, 175-182.	9.9	34
49	Vaccine-Induced Protection of Rhesus Macaques against Plasma Viremia after Intradermal Infection with a European Lineage 1 Strain of West Nile Virus. PLoS ONE, 2014, 9, e112568.	2.5	13
50	T Cell Epitope Mapping of the E-Protein of West Nile Virus in BALB/c Mice. PLoS ONE, 2014, 9, e115343.	2.5	7
51	Comparison of In Vivo Optical Systems for Bioluminescence and Fluorescence Imaging. Journal of Fluorescence, 2013, 23, 909-920.	2.5	26
52	A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Research, 2013, 15, R116.	5.0	91
53	Innate immune response and programmed cell death following carrier-mediated delivery of unmodified mRNA to respiratory cells. Journal of Controlled Release, 2013, 167, 157-166.	9.9	47
54	Coupling of drug containing liposomes to microbubbles improves ultrasound triggered drug delivery in mice. Journal of Controlled Release, 2013, 172, 885-893.	9.9	55

#	Article	IF	CITATIONS
55	Enhancing Nucleic Acid Delivery with Ultrasound and Microbubbles. Methods in Molecular Biology, 2013, 948, 195-204.	0.9	15
56	Comparison of the Gene Transfer Efficiency of mRNA/GL67 and pDNA/GL67 Complexes in Respiratory Cells. Molecular Pharmaceutics, 2012, 9, 2136-2145.	4.6	25
57	Recent progress in canine tumor vaccination: potential applications for human tumor vaccines. Expert Review of Vaccines, 2012, 11, 1375-1386.	4.4	14
58	Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. Journal of Controlled Release, 2012, 158, 362-370.	9.9	175
59	Recent progress in West Nile virus diagnosis and vaccination. Veterinary Research, 2012, 43, 16.	3.0	125
60	Elucidating the Mechanisms Behind Sonoporation with Adeno-Associated Virus-Loaded Microbubbles. Molecular Pharmaceutics, 2011, 8, 2244-2251.	4.6	38
61	Fluorescence single particle tracking for sizing of nanoparticles in undiluted biological fluids. , 2011, , .		0
62	mRNA as gene therapeutic: How to control protein expression. Journal of Controlled Release, 2011, 150, 238-247.	9.9	195
63	Self-assembled liposome-loaded microbubbles: The missing link for safe and efficient ultrasound triggered drug-delivery. Journal of Controlled Release, 2011, 152, 249-256.	9.9	151
64	Lipid-mediated gene delivery to the skin. European Journal of Pharmaceutical Sciences, 2011, 43, 199-211.	4.0	92
65	Connexin32 hemichannels contribute to the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death. Cellular and Molecular Life Sciences, 2010, 67, 907-918.	5.4	31
66	Synergistic effects between natural histone mixtures and polyethylenimine in non-viral gene delivery in vitro. International Journal of Pharmaceutics, 2010, 400, 86-95.	5.2	13
67	Monitoring the disassembly of siRNA polyplexes in serum is crucial for predicting their biological efficacy. Journal of Controlled Release, 2010, 141, 38-41.	9.9	91
68	Adeno-associated virus loaded microbubbles as a tool for targeted gene delivery. Journal of Controlled Release, 2010, 148, e59.	9.9	2
69	Ultrasound responsive doxorubicin-loaded microbubbles; towards an easy applicable drug delivery platform. Journal of Controlled Release, 2010, 148, e59-e60.	9.9	7
70	Tumor cell killing efficiency of doxorubicin loaded microbubbles after ultrasound exposure. Journal of Controlled Release, 2010, 148, e113-e114.	9.9	14
71	Advanced fluorescence microscopy methods illuminate the transfection pathway of nucleic acid nanoparticles. Journal of Controlled Release, 2010, 148, 69-74.	9.9	42
72	Flexible Nanosomes (SECosomes) Enable Efficient siRNA Delivery in Cultured Primary Skin Cells and in the Viable Epidermis of Ex Vivo Human Skin. Advanced Functional Materials, 2010, 20, 4077-4090.	14.9	79

#	Article	IF	CITATIONS
73	Design and Evaluation of Doxorubicin-containing Microbubbles for Ultrasound-triggered Doxorubicin Delivery: Cytotoxicity and Mechanisms Involved. Molecular Therapy, 2010, 18, 101-108.	8.2	275
74	Vaccination of turkeys against Chlamydophila psittaci through optimised DNA formulation and administration. Vaccine, 2010, 28, 3095-3105.	3.8	25
75	Sizing Nanomatter in Biological Fluids by Fluorescence Single Particle Tracking. Nano Letters, 2010, 10, 4435-4442.	9.1	144
76	The Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimization and Pitfalls. Molecular Therapy, 2010, 18, 561-569.	8.2	578
77	Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation. Pharmaceutical Development and Technology, 2009, 14, 358-368.	2.4	27
78	Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: Effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. Journal of Controlled Release, 2009, 138, 148-159.	9.9	173
79	Extracellular barriers in respiratory gene therapy. Advanced Drug Delivery Reviews, 2009, 61, 115-127.	13.7	199
80	Ultrasound Exposure of Lipoplex Loaded Microbubbles Facilitates Direct Cytoplasmic Entry of the Lipoplexes. Molecular Pharmaceutics, 2009, 6, 457-467.	4.6	83
81	Drug loaded microbubble design for ultrasound triggered delivery. Soft Matter, 2009, 5, 2161.	2.7	212
82	Elucidating the Encapsulation of Short Interfering RNA in PEGylated Cationic Liposomes. Langmuir, 2009, 25, 4886-4891.	3.5	51
83	Can Ultrasound Solve the Transport Barrier of the Neural Retina?. Pharmaceutical Research, 2008, 25, 2657-2665.	3.5	19
84	Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(βâ€amino esters). Journal of Gene Medicine, 2008, 10, 783-794.	2.8	58
85	Dextran Microgels for Timeâ€Controlled Delivery of siRNA. Advanced Functional Materials, 2008, 18, 993-1001.	14.9	50
86	Maintaining the silence: reflections on long-term RNAi. Drug Discovery Today, 2008, 13, 917-931.	6.4	106
87	A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum. Journal of Controlled Release, 2008, 126, 67-76.	9.9	119
88	Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles. Journal of Controlled Release, 2008, 126, 265-273.	9.9	115
89	New strategies for nucleic acid delivery to conquer cellular and nuclear membranes. Journal of Controlled Release, 2008, 132, 279-288.	9.9	45
90	Nuclear accumulation of plasmid DNA can be enhanced by non-selective gating of the nuclear pore. Nucleic Acids Research, 2007, 35, e86.	14.5	37

#	Article	IF	CITATIONS
91	Mucolytic activity of bacterial and human chitinases. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 839-846.	2.4	21
92	Cellular entry pathway and gene transfer capacity of TAT-modified lipoplexes. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 571-579.	2.6	63
93	Release mechanisms for polyelectrolyte capsules. Chemical Society Reviews, 2007, 36, 636-649.	38.1	467
94	Nucleic acid delivery: Where material sciences and bio-sciences meet. Materials Science and Engineering Reports, 2007, 58, 117-161.	31.8	88
95	Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. Journal of Controlled Release, 2007, 122, 226-235.	9.9	57
96	Sensitive Spectroscopic Detection of Large and Denatured Protein Aggregates in Solution by Use of the Fluorescent Dye Nile Red. Journal of Fluorescence, 2007, 17, 181-192.	2.5	67
97	Physicochemical and Transfection Properties of Cationic Hydroxyethylcellulose/DNA Nanoparticles. Biomacromolecules, 2006, 7, 2856-2862.	5.4	43
98	Ultrasound-Responsive Polymer-Coated Microbubbles That Bind and Protect DNA. Langmuir, 2006, 22, 7273-7278.	3.5	169
99	In Situ Analysis of Single-Stranded and Duplex siRNA Integrity in Living Cells. Biochemistry, 2006, 45, 10614-10623.	2.5	53
100	Influence of plasmid DNA topology on the transfection properties of DOTAP/DOPE lipoplexes. Journal of Controlled Release, 2006, 115, 335-343.	9.9	101
101	Intracellularly Degradable Polyelectrolyte Microcapsules. Advanced Materials, 2006, 18, 1005-1009.	21.0	313
102	Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax, 2006, 61, 962-966.	5.6	41
103	The Internalization Route Resulting in Successful Gene Expression Depends on both Cell Line and Polyethylenimine Polyplex Type. Molecular Therapy, 2006, 14, 745-753.	8.2	289
104	Vitreous: A Barrier to Nonviral Ocular Gene Therapy. , 2005, 46, 3553.		169
105	On the biological activity of anti-ICAM-1 oligonucleotides complexed to non-viral carriers Journal of Controlled Release, 2004, 96, 207-219.	9.9	12
106	Mobility and stability of gene complexes in biogels. Journal of Controlled Release, 2003, 87, 117-129.	9.9	31
107	Three-Dimensional Fluorescence Recovery after Photobleaching with the Confocal Scanning Laser Microscope. Biophysical Journal, 2003, 85, 2240-2252.	0.5	265
108	On the transport of lipoplexes through cystic fibrosis sputum. Pharmaceutical Research, 2002, 19, 451-456.	3.5	32

#	Article	IF	CITATIONS
109	Interactions between oligonucleotides and cationic polymers investigated by fluorescence correlation spectroscopy. Pharmaceutical Research, 2001, 18, 928-936.	3.5	44
110	The Physical Properties of Biogels and their Permeability for Macromolecular Drugs and Colloidal Drug Carriers. Journal of Pharmaceutical Sciences, 2000, 89, 835-849.	3.3	61